In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data.
Novel steroid-free topical foam effectively controls seborrheic dermatitisOnce-daily ZORYVE® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older
Journal Of The American Academy Of Dermatology Publishes ZORYVE (Roflumilast) Foam, 0.3% Results For Seborrheic Dermatitis From Pivotal Phase 3 Trial menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that Shawn Kwatra, MD will become the next Chair of.
Simple Steps to Strengthen Your Bones webmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webmd.com Daily Mail and Mail on Sunday newspapers.
Insurance-driven profit-based rules hinder appropriate medical treatment, causing patients to face denials, delays, and risky alternatives, compelling doctors to fight for proper care repeatedly.
How to Treat Chin Acne, According to Dermatologists marieclaire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marieclaire.com Daily Mail and Mail on Sunday newspapers.